Read articles from United States of America

September 04, 2026 by github.io

Clinical guidance on e-cigarettes is moving from avoidance towards structured, evidence-informed advice. The SRNT recommendations recognise that adult smokers are already asking clinicians about vaping, and that many need options beyond traditional cessation tools. That shift matters because shared decision-making requires more than caution; it requires clear comparisons between continued smoking, complete switching and nicotine abstinence. Harm reduction belongs in the clinical conversation when it helps patients move away from combustion.

September 04, 2026 by substack.com

Nicotine’s history is far more complex than the way it is usually discussed. The same substance has been framed as poison, dependence driver, medicine and harm reduction tool, depending on dose, delivery and context. That matters because public health debates often flatten nicotine into a single moral category. Better policy starts by separating the substance from the smoke, the risk from the rhetoric, and the product from the purpose it may serve.

September 03, 2026 by snusforumet.se

The gateway theory has shaped nicotine policy for years, often turning vaping into a presumed pathway to smoking rather than a potential route away from it. Challenging that assumption matters because policy should follow observed behaviour, not fears repeated until they sound like evidence. Research that separates correlation from causation can help clarify whether safer nicotine products are driving harm or displacing cigarettes. Public health needs that distinction before it builds restrictions around a theory.

September 03, 2026 by snusforumet.se

The gateway theory has shaped nicotine policy for years, often turning vaping into a presumed pathway to smoking rather than a potential route away from it. Challenging that assumption matters because policy should follow observed behaviour, not fears repeated until they sound like evidence. Research that separates correlation from causation can help clarify whether safer nicotine products are driving harm or displacing cigarettes. Public health needs that distinction before it builds restrictions around a theory.

September 03, 2026 by clearingtheair.eu

Tobacco control loses credibility when opposition to industry turns into opposition to harm reduction itself. Cigarette companies deserve scrutiny, but that does not make every argument for safer nicotine products a tobacco industry tactic. Adult smokers are poorly served by a debate that treats reduced-risk options as contamination rather than opportunity. Public health should be able to reject industry misconduct while still recognising evidence that helps people move away from combustion.

September 01, 2026 by realclearhealth.com

A regulator can make quitting harder even while claiming to protect public health. Delayed approvals, narrow authorisation pathways and hostility towards safer nicotine products can leave adult smokers with fewer legal options than they need. Cigarettes remain widely available while alternatives that may help people switch face barriers that slow or block access. The FDA’s approach should be judged by whether it reduces smoking-related harm, not by how cautious it appears on paper.

August 28, 2026 by substack.com

A JAMA article supporting clinician conversations about e-cigarettes should make the debate more precise. The evidence is strongest for adult smokers who use vaping as a route away from cigarettes, not for vague claims about nicotine use in general. That distinction matters because policy can either support full switching or bury it under uncertainty. Medical guidance should separate evidence from values clearly enough for smokers to understand their options.

August 27, 2026 by ocregister.com

Smokers should not have to fight bureaucracy to reach safer choices. Regulation has a role in setting standards, preventing youth access and protecting consumers, but it should not become a barrier that leaves cigarettes as the easiest product to buy. Harm reduction depends on making lower-risk alternatives available, understandable and legally viable. Public health loses its purpose when process blocks the very options that could reduce harm.

August 27, 2026 by ocregister.com

Smokers should not have to fight bureaucracy to reach safer choices. Regulation has a role in setting standards, preventing youth access and protecting consumers, but it should not become a barrier that leaves cigarettes as the easiest product to buy. Harm reduction depends on making lower-risk alternatives available, understandable and legally viable. Public health loses its purpose when process blocks the very options that could reduce harm.

August 25, 2026 by substack.com

A flavour is not an age group, and regulation becomes weaker when it treats the two as the same. Adults who smoke often rely on flavoured products because taste can make switching away from cigarettes more acceptable and sustainable. Youth access should be prevented through age checks, retailer enforcement and penalties for illegal sales, not by removing options from adults. Public health needs precision: protect young people without making harm reduction less workable for smokers.